community download

Presentation: Set up of phase I unit for viral challenge testing in vaccine development

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Set up of phase I unit for viral challenge testing in vaccine development
·         Discussing regulatory requirements for obtaining permission for viral inoculation studies?
·         Adjusting a phase I unit to perform safely viral challenge testing
·         Using influenza and other viral challenging in prevention and treatment studies
Dr Robert Lins, Senior Clinical Adviser - Clinical Research, SGS Belgium NV

This presentation from Dr Robert Lins discusses the goal, background, methods and results concerning the viral challenge testing in phase 1.

GOAL: to perform virus challenge studies in a Clinical Pharmacology Unit, as proof of concept (POC) trials, after initial activity assessments and phase I human pharmacokinetic (PK) and tolerability studies, and in order to better define the dose ranges to be used in phase II dose ranging trials